膀胱癌：当卡介苗治疗失败时，始终要考虑膀胱外部位。 - Suppr

Suppr

超能文献

Bladder cancer: Always consider extravesical sites when BCG fails.

作者信息

von Rundstedt Friedrich-Carl, Lerner Seth P

机构信息

Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, MC BCM380, Houston, TX 77030, USA.

出版信息

Nat Rev Urol. 2014 Jan;11(1):11-2. doi: 10.1038/nrurol.2013.302. Epub 2013 Dec 17.

DOI:10.1038/nrurol.2013.302

PMID:24346003

Abstract

摘要

相似文献

Bladder cancer: Always consider extravesical sites when BCG fails.膀胱癌：当卡介苗治疗失败时，始终要考虑膀胱外部位。

Nat Rev Urol. 2014 Jan;11(1):11-2. doi: 10.1038/nrurol.2013.302. Epub 2013 Dec 17.

Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.卡介苗治疗失败的患者可能是非肌层浸润性膀胱癌，原因可能是泌尿科医生未能检测到上尿路和尿道的尿路上皮癌。

Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.

Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.卡介苗膀胱内灌注治疗累及前列腺尿道的膀胱浅表性移行细胞癌的长期随访

Clin Genitourin Cancer. 2007 Sep;5(6):386-9. doi: 10.3816/CGC.2007.n.021.

T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.膀胱T1G3移行细胞癌：复发、进展与生存情况

BJU Int. 2004 Jul;94(1):193. doi: 10.1111/j.1464-410X.2004.4949f.x.

Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors.腔内卡介苗治疗浅表性膀胱肿瘤。

J Urol. 2017 Feb;197(2S):S146-S147. doi: 10.1016/j.juro.2016.10.083. Epub 2016 Dec 20.

Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.卡介苗膀胱内灌注治疗膀胱浅表性移行细胞癌后出现膀胱容量减小及多发尿道复发

J Urol. 2001 Feb;165(2):529-30. doi: 10.1097/00005392-200102000-00050.

Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.膀胱浅表性移行细胞癌患者前列腺尿道黏膜受累的保守治疗

Eur Urol. 2004 Apr;45(4):465-9; discussion 469-70. doi: 10.1016/j.eururo.2003.12.014.

[Percutaneous treatment with BCG in multiple upper tract transitional cell carcinoma].

Actas Urol Esp. 2005 Sep;29(8):787-90. doi: 10.1016/s0210-4806(05)73342-8.

Editorial comment.

J Urol. 2009 Oct;182(4):1311-2. doi: 10.1016/j.juro.2009.06.143. Epub 2009 Aug 14.

The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data.全球卡介苗短缺对治疗模式的影响：基于人群的数据。

BJU Int. 2018 Feb;121(2):169-172. doi: 10.1111/bju.14065. Epub 2017 Nov 15.

本文引用的文献

Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.SWOG S0353：吉西他滨膀胱内灌注治疗 2 次卡介苗灌注失败的非肌层浸润性膀胱癌患者的 II 期临床试验。

J Urol. 2013 Oct;190(4):1200-4. doi: 10.1016/j.juro.2013.04.031. Epub 2013 Apr 15.

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.EORTC-GU 癌症组维持卡介苗治疗中高危 Ta、T1 膀胱乳头状癌的随机研究最终结果：三分之一剂量与全剂量和 1 年与 3 年维持治疗。

Eur Urol. 2013 Mar;63(3):462-72. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2.

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.卡介苗康诺特株维持治疗明显延长非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术后无复发生存期。

BJU Int. 2011 Jul;108(2):187-95. doi: 10.1111/j.1464-410X.2010.09891.x. Epub 2010 Dec 22.

Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.己基氨基莱菔素荧光膀胱镜检查在既往接受卡介苗膀胱内灌注治疗的患者中的应用。

BJU Int. 2010 Mar;105(6):789-94. doi: 10.1111/j.1464-410X.2009.08839.x. Epub 2009 Oct 13.

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.对于高危非肌层浸润性膀胱癌患者，诱导性卡介苗（BCG）治疗未能实现完全缓解与疾病恶化和死亡风险增加相关。

Urol Oncol. 2009 Mar-Apr;27(2):155-9. doi: 10.1016/j.urolonc.2007.11.033. Epub 2008 Mar 4.

Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.高危浅表性膀胱肿瘤患者膀胱内卡介苗治疗失败后的膀胱切除术：术前前列腺受累作为一个预后因素。

Eur Urol. 2005 Jul;48(1):53-9; discussion 59. doi: 10.1016/j.eururo.2005.03.021. Epub 2005 Apr 7.

Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.膀胱原位癌患者膀胱内灌注卡介苗：欧洲癌症研究与治疗组织泌尿生殖系统肿瘤协作组II期30861方案的长期结果

Eur Urol. 2001 Aug;40(2):144-50. doi: 10.1159/000049765.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.卡介苗维持免疫疗法用于复发性TA、T1期及原位膀胱移行细胞癌：西南肿瘤协作组的一项随机研究

J Urol. 2000 Apr;163(4):1124-9.

Extravesical tumor relapse in patients with superficial bladder tumors.

J Clin Oncol. 1998 Mar;16(3):1099-102. doi: 10.1200/JCO.1998.16.3.1099.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验